GTC Biotherapeutics (fka GTCB)

[pharm]

From the transcript page 2: "While Leo continues to develop the DIC acquired deficiency in their territories, we will have access to that data for the US. We expect to be working with our US partner on ADDITIONAL acquired-deficiency indications...". The last sentence could refer to the deficiencies that sometimes occur in patients undergoing corony artery bypass surgeries-potentally a $150mm to $200mm-a year market. On page 6 Cox mentions that this treatment could bring GTC into the market more quickly than the DIC itself.